Don’t Let Your Doctor’s Genetics Blind Spot Kill You – Educate Yourself (and your doctor) On ATM Gene Variants and Cancer Prevention

Insomnia, Depression and the Gene That Changed Everything: How PGx Testing Ended Decades of Misdiagnosis

For decades, Mariela Ayala lived under the weight of misdiagnosis—insomnia, depression, recurring infections, medication side effects, and steady weight gain. As prescriptions stacked up (25 at one point), she kept pushing, studying, and showing up for life. But everything changed when a perceptive psychiatrist ordered pharmacogenomic testing. The results: an inherited MTHFR gene variant impacting folate activation which helps control many bodily functions like our metabolism, muscle structure and energy. With that insight, her team introduced methylated B12 and folate, a careful 90-day taper off unnecessary meds, and a return to real, culturally rich foods and herbs. Within weeks she felt energy and clarity return; blood pressure normalized; weight began to fall—ultimately 200 pounds lost holistically. Today, Mariela is “Mari with the 411,” coaching high performers to rebuild identity and standards without abandoning culture. Her story is a rallying cry for patient advocacy, clinician awareness of PGx, and the power of precision medicine to change lives now—not someday. Key takeaways * Advocate for yourself: ask about pharmacogenomic testing and second opinions. * Right form matters: methylated B vitamins and whole, culturally rooted foods supported Mariela’s turnaround. * PGx testing can flag meds to avoid and guide safer, more effective care. META DESCRIPTION Meet Mariela Ayala, who spent 23 years treated for depression and insomnia but never felt well. A perceptive psychologist ordered a pharmacogenomic test and found an MTHFR variant that made it hard for her body to use folate. With answers at last, her plan shifted to methylated B12 and folate, a safe taper off 25 prescriptions, and fresh, flavorful foods from her culture. Within weeks her energy grew; within months her sleep, mood, blood pressure, and weight improved. Today Mariela coaches others to ask better questions, request the right tests, and build simple habits that fit real life. Her story shows how genetics can guide care, prevent years of trial-and-error, and turn fear into hope. Listen to celebrate her courage and learn how PGx can help you and your family. Genetics for Healthcare: A podcast for patients.

Rare Disease = Real Community: Turning Social Media Connections Into Research Partnerships That Drive Precision Medicine Solutions

In this episode Kasey Walsh explains how simple social media connections grew into formal research collaborations, a nonprofit, and a patient‑owned data platform, all motivated by her determination to help her daughter Robbie, who was born with an AP-4 hereditary spastic paraplegia (AP‑4 HSP). She has partnered with institutions like Boston Children's Hospital, the Broad Institute, and the University of Cambridge to move AP‑4 from case reports to research action. Kasey co‑founded Cure AP‑4 and created WinSights [https://winsights.life/] to turn caregiver stories into research data that supports precision medicine. Her work helped find biomarkers, reclassify patients once thought to have cerebral palsy, and start drug‑repurposing studies that identified existing FDA‑approved medicines that showed activity in AP‑4 models. She candidly shares their diagnostic journey to a diagnosis, tips for working with clinicians, and how families can help shape translational research. Listeners who face a rare disease diagnosis will learn how to turn lived experience into real‑world evidence and join a community that helps accelerate precision medicine therapies for children and adults. Key takeaways: - Build community: online groups can lead to treatment opportunities and practical information to make daily life better for a family managing a rare disease. - Own your data: patient‑stewarded health information powers precision medicine studies. - Practical steps: seek genetic testing, connect with specialty centers, and link with advocacy groups (NORD, Global Genes). META DESCRIPTION Looking for hope after a rare disease diagnosis? Hear Kasey Walsh share how her daughter Robbie inspired partnerships with Boston Children's and the University of Cambridge to find treatment for AP-4 hereditary spastic paraplegia (AP-4 HSP). Learn how social media groups became real research teams, and practical steps families can take to find community, resources, and next actions to improve care for rare diseases. We help you learn the language and build confidence to advocate for a precision medicine approach to your health and wellbeing.

INEQUITY KILLS: Access Without Equal Care Drives Preventable Cancer Deaths

EPISODE SUMMARY Rome experienced a career high talking with Dr. Otis W. Brawley, a globally recognized Medical Oncologist and Epidemiologist at the Johns Hopkins Kimmel Cancer Center, about his work to reduce healthcare disparities. Dr Bawley is a former Chief Medical and Scientific Officer of the American Cancer Society, and an author on the recent Report on the Status of Disparities in the United States 2025 [https://pubmed.ncbi.nlm.nih.gov/41400551/]. Rome gets to the heart of why his work has shown that people do not always get the same care inside the health system. Dr Brawley says giving people access to care is not enough. Many patients still get later diagnoses, slower follow‑up, weaker or older treatments, and fewer chances to join clinical trials. These are real, measurable differences caused by provider choices and are at the root of cancer disparities. Key takeaways from this in-depth conversation about disparities: * Care that causes disparities differs in clear ways, including delays in diagnosis and treatment inequity. * Why systemic changes to protocols and measuring clinician adherence beats simple training to deter differential treatment. * Practical solutions like patient navigation and equity metrics to reduce preventable deaths. META DESCRIPTION What if a doctor’s choice—more than the cancer—decides who lives? Dr. Otis W. Brawley, a globally respected voice from the Johns Hopkins Kimmel Cancer Center, showed that black and brown patients often get worse care because doctors make different choices for them: fewer tests, slower follow‑up, less aggressive treatment, or no offer to join clinical trials. These choices come from wrong assumptions about what patients want, limits at busy or underfunded clinics, and they lead to later diagnoses and more deaths in communities of color. We need clear care rules, better tracking of who gets which treatments, and supports like patient navigation so decisions on the quality of care are fair for everyone.

Guardians of the Genome: p53 and the Impact of Li-Fraumeni Syndrome

Journalist Larry Ingrassia [http://www.larryingrassia.com/] speaks candidly with Rome about the years his family spent facing unexplained, early‑onset cancer diagnoses before anyone knew Li‑Fraumeni syndrome existed. He recounts the shock of watching relatives fall ill, the delays in diagnosis, and the sense of powerlessness that followed when no one connected the dots. The lost opportunities for earlier detection and prevention, still weighs heavily in Larry’s work today. As an advocate, he champions routine germline TP53 testing for families with suspicious cancer patterns, pushes for access to specialized surveillance programs, and partners with clinicians to translate genetic results into concrete prevention plans. Larry seeks to spare other families the years of uncertainty his endured and to make early detection and prevention the norm rather than the exception. Listen for these key takeaways from this conversation: * Learn how p53 normally guards the genome, and why inherited p53 mutations dramatically raise cancer risk. * Why unrecognized Li‑Fraumeni syndrome can lead to preventable delays in cancer detection and treatment across generations. * How genetic testing and tailored surveillance can turn a family mystery into a cancer prevention and early‑detection plan. A Fatal Inheritance was named to the 2024 Best Non-Fiction Book list on Amazon! [https://www.amazon.com/b/ref=s9_bw_cg_BOTY23BC_3d1_w?node=17296234011&pf_rd_m=ATVPDKIKX0DER&pf_rd_s=merchandised-search-10&pf_rd_r=SNJ345NGVYRVTTC2EQ8K&pf_rd_t=101&pf_rd_p=b3893904-df7d-4c33-b684-acefc75dc39d&pf_rd_i=17276804011] Learn more from the Li-Fraumeni Syndrome Association [https://www.lfsassociation.org/] META DESCRIPTION What if your family kept getting strange, early cancers and no one could explain why? In this episode, author and journalist Larry Ingrassia tells how Li‑Fraumeni syndrome, a rare inherited change in the TP53 gene, was the missing answer for his family. TP53 makes a protein called p53 that helps fix damaged DNA or tells broken cells to die. When TP53 does not work as it should, people can get many kinds of cancer at a young age. Larry shares how years of confusion and missed chances to find cancer early cost his family time and peace of mind. He explains, in plain words, how a simple genetic test can find the TP53 change and how regular, careful medical checks can help prevent or catch cancer sooner. Our hope is that other families will learn, get tested, and use prevention so fewer people go through what his family did. Learn the language and build the confidence to be an effective advocate for a precision medicine approach to your health!

Precision Medicine Saves Dollars & Makes Sense: How Population Health Screening Can Save Lives for Less

Where did you grow up and what attracted you to a career in medicine? What is precision medicine? This phrase has been used primarily to describe a different approach to cancer care. * tumor profiling – molecular characterization of a person’s cancer cells what drives it * but your POV is prevention, and implementing an pathway to integrate genetics and genomic information into the healthcare ecosystem to be acted upon at different points of care along a patient’s journey When you started to build the program at The Christ Hospital in Cincinnati, how did you decide what you were going to go after? [HerCan testing + PGx] * early detection -- St I-II * prevention – prophylactic surgery * avoid side-effects or drug interactions [adverse events] You must compete for resources. What motivated the hospital to want to invest in this kind of program which does not yield ROI immediately? * Was there pushback? * Who needs to champion this vision and work? What were the results? * # patients tested * people in high-risk programs * money saved on unnecessary procedures or therapy BOD of MADP Alliance for Disease Prevention- Forgot to mention: MADP has rebranded from "Microbiome Alliance for Disease Prevention" to simply "MADP Alliance for Disease Prevention." Founders wanted to focus on Microbiome, but we've dramatically expanded scope :) CDC Chronic Disease fast facts [https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html] Addressing Chronic Disease Medicare—93% & Medicaid—82% in 2022 – chronic disease spending People with chronic disease use a disproportionate share of health care resources 90% prescription drugs = $4.5 trillion 3-of-every 4 (75%) healthcare dollars spent on people with chronic conditions * Diabetes [https://www.google.com/search?q=Diabetes&rlz=1C5CHFA_enUS608US608&oq=recent+numbers+on+healthcare+spending+on+top+10+chronic+diesases+in+the+US&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIGCAEQIRgKMgcIAhAhGI8C0gEJNDcxNzhqMGo0qAIAsAIA&sourceid=chrome&ie=UTF-8&mstk=AUtExfDnf-ha8zisHuMdKkVY44nNZfBhYN09uCXhc_0fu62voyA82wONLW_JufNc61we4xSDU9DF7198ZWlqgLNFODVC7tC14Mz3lu8gNDzHBFI9U00vkqJxAwwZEn5EJaCVkCDUUGIXutBYm_9CxfR2wLegJy_9k33hqw4IQxgnJVRvn2U&csui=3&ved=2ahUKEwjMnLH1mdWTAxW1lmoFHbxqHrUQgK4QegQIAxAB]: ~$413 billion (2022) in medical costs and lost productivity. * 38M have diabetes + 98M pre-diabetes * CKD $96 billion * Heart Disease & Stroke $234 Billion/yr 🡺 $2 trillion by 2025 * kills more American than anything (1-in-4 deaths) * HBP $79 billion Employers loss of productivity – people w/top 10 chronic conditions absent/person ea yr = 164M work days lost = $184 billion in lost productivity * Depression – 25.6 days * Cancer 17 days * Respiratory – 15 * Asthma – 12 * Migraines – 11 * Allergies – 8 * Heart Disease – 6 * Arthritis – 6 * Diabetes – 2 * HBP – 1